This year we learned the story of medical tourist Jim Gass, a corporate executive who hoped to have the results of a stroke healed with stem-cell treatments at a Mexican clinic and instead ended up with a strange, sticky mass in his spine. But you don’t need to go overseas for dodgy treatments never approved by the FDA. At least 351 U.S. businesses operating in a regulatory gray zone are promising that stem cells will treat everything from sports injuries to Alzheimer’s disease. “The clinics are doing an unapproved and for-profit gigantic human experiment,” according to stem cell scientist Paul Knoepfler.
Five poems about the mind
Work reinvented: Tech will drive the office evolution
As organizations navigate a new world of hybrid work, tech innovation will be crucial for employee connection and collaboration.
Investing in people is key to successful transformation
People-related factors like talent attraction and retention and clear top-down communication will determine whether your transformation progresses or stalls.
The way forward: Merging IT and operations
Digital transformation in any industry begins with bridging the gap between two traditionally separate teams.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.